EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors

Katherine R Tuttle

Journal of Clinical Investigation · 01.03.2023 · 133 (5)

DOI: 10.1172/jci167700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.03.2023. Verfasst von Katherine R Tuttle. Beteiligte Einrichtung: Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The sodium-glucose cotransporter-2 (SGLT2) is expressed on the luminal side of proximal tubule epithelial cells in the kidney. While pharmacological inhibition of SGLT2 provides kidney protection in diabetic kidney disease (DKD), the molecular mechanisms remain unclear. In this issue of the JCI, Schaub et al. report on the changes in single-cell transcriptional profiles of young participants with type 2 diabetes who received SGLT2 inhibitors. Treatment with SGLT2 inhibitors restored metabolic perturbations in proximal tubular cells and reduced expression of the inflammatory signaling molecule mTORC1. Notably, changes in transcripts and mTORC1 were also found in the kidney of a diabetes mouse model treated with an SGLT2 inhibitor, supporting use of this model for further studies. These findings reveal cellular mechanisms of SGLT2 inhibitors and are important for advancing therapeutic targets in the treatment of DKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2AnimalsMiceSodium-Glucose Transporter 2KidneyMechanistic Target of Rapamycin Complex 1

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2Mechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA.
  • Division of Nephrology, University of Washington School of Medicine, Seattle, Washington, USA.

Förderung

  • NIMHD NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • CDC HHS

Zitieren

APA

Tuttle, K. R. (2023). Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. Journal of Clinical Investigation, 133(5). https://doi.org/10.1172/jci167700

Vancouver

Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. Journal of Clinical Investigation. 2023;133(5). doi:10.1172/jci167700

BibTeX
@article{Tuttle2023,
  author = {Tuttle, Katherine R},
  title = {Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {5},
  doi = {10.1172/jci167700}
}
Kostenlos starten →